Brilliant Violet 510™ anti-mouse CD3

Antibodies Single
Sony
17A2
Flow Cytometry
Rat IgG2b, κ
Mouse
γδTCR-positive T-T hybridoma D1
1101170
$267.00

Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. For flow cytometric staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (IP, IHC, Activ, CMCD)
2. Mysliwietz J, et al. 1992. Blood 80:2661. (Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (CMCD)
4. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
5. Zan H, et al. 2005. EMBO J. 24:3757.
6. Morgado P, et al. 2011. Infect Immun. 79:4401. PubMed
7. Xiao J, et al. 2012. Arterioscler Thromb Vasc Biol. 32:386. PubMed
8. Cabrera-Perez J, et al. 2015. J Immunol. 194:1609. PubMed